CD8A and neoplasm: mJX-594 treatment increased effector T cell and TCF1+ stem-like T cell expression among cancer-specific CD8+ T cells in the tumor tissue and spleen; anti-PD-1 antibody further increased these cells, which was important for therapeutic efficacy.